



SUMMARY OF THE TERMS AND CONDITIONS

For additional product and risk information, please consult Sales Prospectus

Bloomberg: SPGCAPG

Product Details

Underlying S&P GSCI Agricultural Excess Return IndexTM (Quanto in EUR) EURO 100.00 / Settlement Price of the Underlying on the Issue Date, i.e. Ratio 1.667603 Index refers to 1 certificate Underlying Level 59,9663 index point

Issue Price **EUR 100**

Final Reference Price of Underlying Settlement Price of the Underlying on the Valuation Date as published by ("Index (Final)") the Index Sponsor. The Valuation Date is the Exercise Date or the

Termination Date.

Redemption Amount Cash Redemption in EUR in case of Exercise or Termination on the

Redemption Date of the Settlement Amount. The Settlement Amount will

be calculated as according to the following formula:

[Index (Final) $-\sum$ Currency Hedging Fee] * Ratio

n= number of calendardays since Payment Date

Ratio= 1.667603

Security Identification Codes

ISIN: CH0022983982 Valor: 2298398 WKN: UB9AAC

Common Code: 023247534

Dates

07 10 2005 Issue Date 11.10.2005 Payment Date

Last Trading Day 2 exchange trading days prior to the termination date

Expiration Date

5 Geschäftstage/business days after the Valuation Date Redemption Date

Date of Investor's Exercise Right Exercise Date Date of Issuer's Call Right **Termination Date**

General Information

UBS AG, London Branch Issuer

Rating Aa2/AA+

Standard and Poor's Index Sponsor Lead Manager UBS Limited, London Issue Size 200,000 Certificates 09:00 - 17:30 hours Trading

Listing Frankfurt, Stuttgart (Third Section)

Minimum Trading Size 1 Certificate

Smart / Euwax Max. Spread (homogenised): 5%

Min.Size: 100 Certificate(s) U.S.A.; U.S. Persons / U.K.

Sales Restrictions Euroclear, Clearstream Banking AG, Clearstream Banking S.A. (Global Clearing

Certificate at Clearstream Banking AG)

Clearstream Banking AG eligible (up-to Global Certificate) Custody

Applicable Law German Law Place of Jurisdiction Frankfurt am Main

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS's trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price ror rebates to them for their own account some proportion of the issue price. Purther information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or induciary in any transaction to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Notes (the Prospectus). UBS makes no representation o

r reproduced without UBS's prior written permission.
o action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in
e Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.
ources: Company/Index Description: Bloomberg; Chart: Reuters

Contact

UBS Deutschland AG Investment Products Stephanstrasse 14-16 60313 Frankfurt am Main

Germany

Phone: +49 (0) 69 1369 - 8989 Fax: +49 (0) 72 22 73 email: invest@ubs.com Internet: www.ubs.com/keyinvest Reuters: UBSDFFW02 Videotext: n-tv page 875ff.

Bloomberg: UWNT





SUMMARY OF THE TERMS AND CONDITIONS

For additional product and risk information, please consult Sales Prospectus Issuer's Call Right

The Issuer has a right to call the Certificates for early redemption by giving notice to that effect. The Certificates can be terminated for the first time 1 year and 6 months after the Payment Date and the termination becomes effective after a notice period of 3 months, for the value of the current Settlement Amount. The Valuation Date is the Termination Date.

Investor's Exercise Right:

Despite the fact that the Certificates can be sold daily on the above mentioned stock exchanges, the Investor has an annual right to exercise his Certificates (notice to be received no later than 10:00 am, local time Frankfurt am Main, on 11 October.) effective 11 October of the relevant year, for the value of the current Settlement Amount. The Valuation Date is the Exercise Date.

Description of the S&P GSCI Index Family

By design, the S&P GSCI indices reflect a passive portfolio of long positions in futures. The Index components are updated on a yearly basis. The Excess Return index measures the uncollateralized return from rolling futures forwarded each month. For more detailed information on indices see the S&P www.indices.standardandpoors.com/

The UBS Open End Certificate on S&P GSCI Agricultural Excess Return Index™ (Quanto in EUR) tracks the performance of S&P GSCI Agricultural Excess Return Index™, adjusted by the Quanto (currency hedge) effect. The Currency Hedging Fee covers the expenses/yields of providing the Quanto overlay and is determined by the following variables:

- [1] The interest rate differential between currency of the underlying and quanto currency
- [2] The volatility of the FX pair
- [3] The volatility of the underlying commodity index
- [4] The correlation between the FX pair and the underlying index

The Currency Hedging Fee will be added respective deducted on a daily basis, by which expenses or yields the certificate perform differently compared to the underlying index.

Initial Currency Hedging Fee: 1,25% p.a. . The Currency Hedging Fee will potentially change on a daily basis.

Certificates are a group of products, which replicate the performance of the underlying. Certificates give the investor the possibility to be diversified with relatively low administrative costs and small investment amounts. The risk of loss is limited to the invested capital. The Investor assumes the credit risk of UBS AG.

Selling Restrictions

Any Product purchased by any person for resale may not be offered in any jurisdiction in circumstances, which would result in the Issuer being obliged to register any further prospectus or corresponding document relating to the Product in such jurisdiction.

Holders of this Product are advised to read the selling restrictions described more fully in the relevant prospectus or information memorandum of this Product. The restrictions listed below must not be taken as

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS's trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price ror rebates to them for their own accounts one proportion of the issue price. Purther information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the eventer you consider in necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or induciary in any transaction. This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the information Memora

r reproduced without UBS's prior written permission.
o action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in le Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

Jurces: CompanyIndex Description: Bloomberg, Chart: Reuters or reproduced without UBS's prior written permi:

Contact

UBS Deutschland AG Investment Products Stephanstrasse 14-16 60313 Frankfurt am Main Germany

Phone: +49 (0) 69 1369 - 8989 Fax: +49 (0) 72 22 73 email: invest@ubs.com Internet: www.ubs.com/keyinvest Reuters: URSDFFW02 Videotext: n-tv page 875ff.

Bloomberg: UWNT





SUMMARY OF THE TERMS AND CONDITIONS

For additional product and risk information, please consult Sales Prospectus

definitive guidance as to whether this Product can be sold in a jurisdiction. Holders of this Product should seek specific advice before on-selling it.

Europe – For EEA jurisdictions (EU member states plus Norway, Iceland and Liechtenstein) that have implemented the EU Prospectus Directive, the Final Terms and Base Prospectus for these Notes DO NOT QUALIFY as a prospectus published in accordance with the requirements of the EU Prospectus Directive. Unless and until a prospectus has been published in accordance with the requirements of the EU Directive, these Notes may not be offered or sold other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies) or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 investors that are not Qualified Investors per EEA jurisdiction. A "Qualified Investor" is a legal entity that (i) is authorised or regulated to operate in the financial markets or has the sole purpose to invest in securities; or (ii) meets two of the following three criteria (as shown in its last annual or consolidated accounts): (a) an average number of at least 250 employees during the last financial year; (b) a total balance sheet of more than EUR 43,000,000; and (c) an annual net turnover of more than EUR 50,000,000.

For EEA jurisdictions that have not implemented the EU Prospectus Directive, sales must be in compliance with the law of that jurisdiction.

Hong Kong - This Product has not been offered and sold, and each purchaser represents and agrees that it will not offer and sell the Product in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy and sell shares or debentures, whether as principal or agent, or in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) of Hong Kong or to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance, or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance. In relation to the issue of this Product, each purchaser represents and agrees that it has not issued and will not issue any advertisement, invitation or document relating to the Product, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Product which is or is intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance and any rules made thereunder.

Luxembourg - This Termsheet and the Terms and Conditions related to this product has not been approved by and will not be submitted for approval to the competent authorities in Luxembourg (Commission de Surveillance du Secteur Financier and Luxembourg Stock Exchange) and consequently are not authorised for public offering in Luxembourg. The Termsheet or other marketing material may therefore not be distributed and the product not be offered in Luxembourg other than (1) to Qualified Investors in the meaning of the Luxembourg Law on prospectuses for securities of 10 July 2005, (2) to persons who invest in the product for a minimum sum of 50.000 EUR for each investment or (3) to up to 100 persons not qualified a Qualified Investors in the above-mentioned

Singapore - This Termsheet and the Terms and Conditions relating to this Product have not been registered as a prospectus with the Monetary Authority of Singapore (the "MAS") under the Securities and Futures Act (Cap. 289) of Singapore (the "Securities and Futures Act"). Accordingly, the Product may not be offered or sold or made the subject of an invitation for subscription or purchase nor may this Term sheet and the Terms and Conditions or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of such Product be circulated or distributed, whether directly or indirectly, to the public or any member of the public in Singapore other than (1) to an institutional investor or other person falling within Section 274 of the Securities and Futures Act, (2) to a sophisticated investor (as defined in Section 275 of the Securities and Futures Act) and in accordance with the conditions specified in Section 275 of the Securities and Futures Act or (3) otherwise than pursuant to, and in accordance with the conditions of, any other applicable provision of the Securities and Futures Act.

UK – This Product should not be sold with a consideration of less than €50,000 or equivalent.

USA – This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG.

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS's trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price or rebates to them for their own accounts one proportion of the issue price. Purther information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the eventer you consider in necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fluduciary in any transaction. This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memor

reproduced without UBS's prior written permission.
o action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in ler Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

Jurces: CompanyIndex Description: Bloomberg, Chart: Reuters

Contact

UBS Deutschland AG Investment Products Stephanstrasse 14-16 60313 Frankfurt am Main Germany Phone: +49 (0) 69 1369 - 8989

Fax: +49 (0) 72 22 73 email: invest@ubs.com Internet: www.ubs.com/keyinvest Reuters: UBSDFFW02 Videotext: n-tv page 875ff. Bloomberg: UWNT





SUMMARY OF THE TERMS AND CONDITIONS For additional product and risk information, please consult Sales Prospectus

Index-Disclaimer:

The Product is not sponsored, endorsed, sold or promoted by Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P"). Standard & Poor's does not make any representation or warranty, express or implied, to the owners of the Products or any member of the public regarding the advisability of investing in securities generally or in the Product particularly or the ability of the S&P Indices to track general stock market performance. S&P's only relationship to UBS AG is the licensing of certain trademarks and trade names of S&P and of the S&P Indices, which indices are determined, composed and calculated by S&P without regard to UBS AG or the Product. S&P has no obligation to take the needs of UBS AG or the owners of the Product into consideration in determining, composing or calculating the S&P Indices. S&P is not responsible for and have not participated in the determination of the timing of, prices at, or quantities of the Product to be issued or in the determination or calculation of the equation by which the Product are to be converted into cash. S&P has no obligation or liability in connection with the administration, marketing or trading of the Product.

S&P DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE S&P INDICES OR ANY DATA INCLUDED THEREIN AND S&P SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. S&P MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY UBS AG, OWNERS OF THE PRODUCT OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE S&P INDICES OR ANY DATA S&P MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE S&P INDICES OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL S&P HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

The S&P Marks are trademarks of The McGraw-Hill Companies, Inc. and have been licensed for use by UBS AG E: For Swiss paying agents, the product is not subject to the EU Savings Tax (TK14).

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS's trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price or rebates to them for their own accounts one proportion of the issue price. Purther information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the eventer you consider in necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fluduciary in any transaction. This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memor

reproduced without UBS's prior written permission.

a earting in a reproduced without UBS's prior written permission.

a cation has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in e Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

purces: CompanyIndex Description: Bloomberg, Chart: Reuters

Contact

UBS Deutschland AG Investment Products Stephanstrasse 14-16 60313 Frankfurt am Main Germany

Phone: +49 (0) 69 1369 - 8989 Fax: +49 (0) 72 22 73 email: invest@ubs.com Internet: www.ubs.com/keyinvest Reuters: UBSDFFW02 Videotext: n-tv page 875ff. Bloomberg: UWNT